Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1

Journal Article · · Experimental Cell Research
;  [1];  [2]; ; ; ; ;  [3];  [3]
  1. Research Institute of Atherosclerotic Disease, Xi’an Jiaotong University Cardiovascular Research Center, Xi’an, Shaanxi 710061 (China)
  2. School of Pharmacy, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi 710061 (China)
  3. Department of Pharmacology, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi 710061 (China)

Recent studies demonstrated that the ligand-activated transcription factor peroxisome proliferator-activated receptorα (PPARα) acts in association with histone deacetylase sirtuin 1 (SIRT1) in the regulation of metabolism and inflammation involved in cardiovascular diseases. PPARα activation also participates in the modulation of cell apoptosis. Our previous study found that SIRT1 inhibits the apoptosis of vascular adventitial fibroblasts (VAFs). However, whether the role of PPARα in apoptosis of VAFs is mediated by SIRT1 remains unknown. In this study, we aimed to determine the effect of PPARα agonist fenofibrate on cell apoptosis and SIRT1 expression and related mechanisms in ApoE{sup −/−} mice and VAFs in vitro. We found that fenofibrate inhibited cell apoptosis in vascular adventitia and up-regulated SIRT1 expression in aorta of ApoE{sup −/−} mice. Moreover, SIRT1 activator resveratrol (RSV) further enhanced these effects of fenofibrate. In vitro study showed that activation of PPARα by fenofibrate inhibited TNF-α-induced cell apoptosis and cell cycle arrest in VAFs. Meanwhile, fenofibrate up-regulated SIRT1 expression and inhibited SIRT1 translocation from nucleus to cytoplasm in VAFs stimulated with TNF-α. Moreover, the effects of fenofibrate on cell apoptosis and SIRT1 expression in VAFs were reversed by PPARα antagonist GW6471. Importantly, treatment of VAFs with SIRT1 siRNA or pcDNA3.1(+)-SIRT1 showed that the inhibitory effect of fenofibrate on cell apoptosis in VAFs through SIRT1. On the other hand, knockdown of FoxO1 decreased cell apoptosis of VAFs compared with fenofibrate group. Overexpression of FoxO1 increased cell apoptosis of VAFs compared with fenofibrate group. Further study found that fenofibrate decreased the expression of acetylated-FoxO1 in TNF-α-stimulated VAFs, which was abolished by SIRT1 knockdown. Taken together, these findings indicate that activation of PPARα by fenofibrate inhibits cell apoptosis in VAFs partly through the SIRT1-mediated deacetylation of FoxO1. - Highlights: • Fenofibrate inhibits apoptosis and increases SIRT1 expression in vivo and in vitro. • Fenofibrate inhibits cell apoptosis in VAFs through SIRT1. • Fenofibrate inhibits apoptosis through SIRT1-mediated deacetylation of FoxO1. • Fenofibrate inhibits apoptosis and increases SIRT1 expression via PPARα activation.

OSTI ID:
22746367
Journal Information:
Experimental Cell Research, Journal Name: Experimental Cell Research Journal Issue: 1 Vol. 338; ISSN 0014-4827; ISSN ECREAL
Country of Publication:
United States
Language:
English

Similar Records

PPARα agonist fenofibrate attenuates TNF-α-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway
Journal Article · Mon Jun 10 00:00:00 EDT 2013 · Experimental Cell Research · OSTI ID:22267811

Role of resveratrol in FOXO1-mediated gluconeogenic gene expression in the liver
Journal Article · Thu Dec 16 23:00:00 EST 2010 · Biochemical and Biophysical Research Communications · OSTI ID:22204713

Fenofibrate activates Nrf2 through p62-dependent Keap1 degradation
Journal Article · Fri Sep 25 00:00:00 EDT 2015 · Biochemical and Biophysical Research Communications · OSTI ID:22458561